Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Summit Therapeutics PLC (SMMT) had Free Cash Flow per Share of $-0.16 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-189.42M |
|
-- |
|
-- |
|
$189.42M |
|
$-189.42M |
|
-- |
|
$-189.42M |
|
$-189.42M |
|
$-189.42M |
|
$-189.42M |
|
$-189.42M |
|
$-189.42M |
|
$-189.42M |
|
$-189.38M |
|
775.46M |
|
775.46M |
|
$-0.24 |
|
$-0.24 |
|
| Balance Sheet Financials | |
$616.60M |
|
$1.66M |
|
$31.26M |
|
$647.86M |
|
$83.27M |
|
-- |
|
$18.66M |
|
$101.92M |
|
$545.93M |
|
$543.97M |
|
$545.93M |
|
776.02M |
|
| Cash Flow Statement Financials | |
$-122.29M |
|
$-0.24M |
|
$3.80M |
|
$225.58M |
|
$106.83M |
|
$-118.75M |
|
$72.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-122.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.70% |
|
-34.82% |
|
-29.24% |
|
-34.70% |
|
$0.70 |
|
|
Free Cash Flow per Share |
$-0.16 |
$-0.16 |
|